Board of Directors

You are here: Home » About » Our Leadership » Board of Directors

Dr. Mohammad Afshar: CEO, Ariana Pharma

Mohammad is the President and CEO of Ariana Pharmaceuticals and founded the company in 2003. Prior to this, Mohammad was one of the founders and the Director of Drug Design and IT at RiboTargets, Cambridge, UK, leading the computer aided discovery of novel anti infective and oncology molecules.   Before joining RiboTargets, Mohammad held several positions in academic institutions including the Department of Chemistry at the University of York, UK, and the CRBM of the CNRS in France. He holds a Medical Degree (DCEM), MPhil in Computer Science (DEA), a PhD in structural biochemistry and a “Habilitation doctorate” (HDR) from the Faculty of Medicine of the University of Montpellier, France.  He is currently involved with a number of charities, including the Cystic Fibrosis foundation

Daniel Bernier: CEO, Euracier

Daniel is the CEO of Euracier, a leading French company focussed on specialized steel. Founded in 1973, today, Euracier employs 20 people in France and has annual sales of approximately 8M€.

Adam Afshar: President, Hyde Park Global Investments

Hyde Park Global Investments is a leading mathematical trading firm based in Atlanta, USA. Adam holds an MBA from the University of Chicago.

Karine Lignel: Investment Director, CM-CIC Capital Innovation

Karine is an Engineer (food science, ENSIA with a Master’s degree in finance and economics (IGIA, part of ESSEC). She has seven years of experience in the food industry, mainly in technical positions. She joined venture capital since 2000, investing mainly in life sciences. Since 2000, she has been appointed to more than 10 board memberships.

CM-CIC Capital Innovation is the venture capital subsidiary of the CIC – CM-CIC Capital Group. Its objective is to invest in promising technology companies in their early stages of development with a high growth potential in dynamic sectors such as information technologies, telecommunications, electronics, life sciences, new materials, and the environment.

Non-executive board member
Dr. Isabelle Buckle: Vice-President Research Applications and Industrial Relations, Institut Pasteur

Prior to taking up her current position at Institut Pasteur, Isabelle was Global Vice-President Clinical Mass Spectrometry at Bruker Daltonics, her role being to propose innovative clinical solutions to opinion leaders and to identify future solutions. In 2010, Dr. Buckle was appointed Chief Executive Officer of InGen BioSciences, a group that is developing multiparameter tests for infectious diseases and distributing innovative in vitro diagnostic tests for clinical use. Before directing this group, she worked for five years as Director for Global Business Development for major pharmaceutical accounts at Applied Biosystems, which subsequently became Life Technologies (now Thermo Fisher). Prior to this role, Isabelle spent six years at Ciphergen Biosystems, an innovative, cutting-edge proteomics company, where she was Regional Director for Southern Europe, Belgium and Switzerland, then Head of Diagnostic Development for Europe, responsible for cooperation with clinical and pharmaceutical institutions. Before joining Ciphergen Biosystems, Dr. Buckle worked for nine years at Amersham Pharmacia Biotech (now GE), where she moved up through a variety of positions, ending up as European Sales and Marketing Director in the Non-industrial Chromatography Division.

Isabelle Buckle holds a Master’s degree in Biochemistry and a PhD in Microbiology from the University of Paris VII, which she completed at the Institut Pasteur.

Non-executive board member
Dr. Felix Frueh: CEO, Intellos Health LLC

Thought leader in personalized medicine with twenty years of R&D, management and policy experience. Co-Founder and CEO of Intellos Health LLC, a new diagnostic business. Prior, he was Chief Scientific Officer at Human Longevity, Inc. and Entrepreneur-in-Residence at Third Rock Ventures. Dr. Frueh was President of the Medco Research Institute, leading the PBM’s research initiatives in health economics and outcomes research. Prior to Medco, he was the first Associate Director for Genomics at the FDA, where he oversaw the development and implementation of policies around biomarker qualification and companion diagnostics. Dr. Frueh received his education at Stanford University and the University of Basel in Switzerland, where he graduated magna cum laude in biochemistry

Non-executive board member
Dr. Christian M. Policard, Ph.D: Founder, Bio Development Conseil

Christian specializes in biotechnology and healthcare in France.  Dr. Policard served as Vice President and Head of Applications at Pasteur Institute. He served as the President of Bio-Rad Pasteur S.A.  Dr. Policard served as the Vice President of Sanofi. He served as the Chairman of Cellectis until June 27, 2011.  He serves as a Director of France Biotech